CME

Host: Lee P. Shulman, MD, FACMG, FACOG

Guest: Kenneth J. Moise Jr., MD

This program is no longer available for credit.

Program Chairman:
Roberto Romero M.D. D.Med Sci.
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.

Guest: Neera Dahl, MD, PhD

Guest: Craig E. Gordon, MD

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

This activity is not available for continuing education credit.

Host: Ayse Tuba Kendi, MD

Guest: A. Oliver Sartor, MD

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).

In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.

Host: William Mencia, MD, FACEHP, CHCP

Guest: Julie Blatt, MD

Guest: Taizo Nakano, MD

PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.

The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.

Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.

Guest: Sara A. Hurvitz, MD, FACP

HER2-Directed ADCs in Breast Cancer

Guest: Gregory Pokrywka MD FACP FNLA NCMP

Guest: Karol karol

Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.

Host: Jennifer Caudle, DO

Guest: Mikkael A. Sekeres, MD, MS

Guest: Sara M. Tinsley, PhD, ARNP, AOCNP

Please note: This activity is no longer available for continuing education credit.

There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.

Guest: Arlene B. Chapman, MD

Guest: Michel Chonchol, MD

This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.

Guest: Michel Chonchol, MD

Guest: Frederic Rahbari-Oskoui, MD, MSc

This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.

Guest: Matthew B. Lanktree, MD, PhD

Guest: Neera Dahl, MD, PhD

This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.